Starting GLP-1 Treatment in 2026: A Clinician's Guide to the Right First Steps

Starting GLP-1 medication is one of the most consequential health decisions you can make in 2026. These medications — semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — have demonstrated remarkable efficacy in clinical trials. But the gap between reading about results online and actually beginning treatment safely is wider than most patients realize.

This guide walks through the clinical process of starting GLP-1 treatment the right way, from the initial eligibility conversation to your first few weeks on medication.

Who Is Clinically Eligible for GLP-1 Treatment?

The eligibility criteria for GLP-1 weight management medications are well-established, though individual providers may apply additional screening. Generally, you may be a candidate if you meet one of these profiles:

• BMI of 30 or above (obesity) with or without weight-related comorbidities
• BMI of 27 or above (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea

Your provider should also assess whether you have any contraindications. GLP-1 receptor agonists are not appropriate for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). A history of pancreatitis requires careful evaluation, and pregnancy or active plans to become pregnant within the near term are also contraindications.

Choosing Your First GLP-1 Medication

Most patients starting GLP-1 treatment in 2026 will begin with either semaglutide or tirzepatide. Here's how clinicians typically approach that decision:

Semaglutide has the longest track record, with FDA approval for weight management (as Wegovy) since 2021 and extensive cardiovascular outcome data from the SELECT trial. It works by mimicking the GLP-1 hormone, reducing appetite and slowing gastric emptying. Available as a weekly injection or daily oral tablet.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it targets two incretin hormones rather than one. The SURMOUNT trials demonstrated higher average weight loss compared to semaglutide (approximately 20-25% of body weight vs. 15-17%), though individual responses vary considerably. Currently available as a weekly injection.

Neither medication is categorically "better." The clinical decision depends on your metabolic profile, insurance coverage, tolerance for injection frequency, and whether the higher average efficacy of tirzepatide outweighs semaglutide's longer safety track record for your specific situation.

The Compounded vs. Brand-Name Decision

One of the most important decisions new patients face is whether to use brand-name FDA-approved medications or compounded versions. This choice has significant clinical, financial, and regulatory dimensions.

Brand-name medications (Wegovy, Zepbound) have undergone rigorous FDA clinical trials and carry FDA approval. They're manufactured under strict cGMP conditions. The downside: they can cost $1,000+ per month without insurance, and coverage remains inconsistent.

Compounded semaglutide and tirzepatide are prepared by state-licensed compounding pharmacies under 503A or 503B regulations. They offer substantially lower costs — often $99 to $299 per month — but are not FDA-approved as finished products. The active pharmaceutical ingredients (APIs) are the same, but manufacturing oversight differs.

What Good Clinical Onboarding Looks Like

A quality provider — whether in-person or telehealth — should conduct the following before prescribing your first dose:

• Complete medical history review including current medications, supplements, and prior weight loss attempts
• Baseline lab work — at minimum: comprehensive metabolic panel (CMP), A1C, lipid panel, and thyroid function (TSH). Some providers also order kidney function markers (eGFR, BUN/creatinine)
• Contraindication screening for thyroid cancer history, pancreatitis, gallbladder disease, and pregnancy
• Mental health screening — particularly important given emerging data on GLP-1 effects on mood and suicidal ideation
• Clear treatment plan including titration schedule, follow-up cadence, and what to do if side effects arise

If a provider offers to prescribe without any of these steps, that's a clinical red flag worth taking seriously.

Your First Weeks on GLP-1 Medication

Every GLP-1 medication starts at a low dose and titrates upward over weeks to months. This isn't optional — it's essential for minimizing gastrointestinal side effects and allowing your body to adjust.

For semaglutide, the standard titration begins at 0.25 mg weekly for four weeks, then increases to 0.5 mg. Clinical dose escalation continues through 1.0 mg, 1.7 mg, and up to the maintenance dose of 2.4 mg, with each step lasting at least four weeks.

For tirzepatide, the initial dose is 2.5 mg weekly for four weeks, increasing to 5 mg, then 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg.

Common First-Month Experiences

Appetite reduction is typically noticeable within the first week or two. Many patients describe it as a quieting of food noise — the constant background chatter about what to eat next simply fades.

Nausea is the most common side effect, affecting roughly 40-50% of patients at some point during titration. It's usually mild to moderate and most pronounced in the first few days after each dose increase. Strategies that help: eating smaller meals, avoiding high-fat foods, staying hydrated, and timing your injection to coincide with a day you can rest if needed.

Constipation is the second most common GI effect. Adequate hydration (aim for 80+ oz daily), fiber intake, and movement help significantly. If it persists, your provider may recommend a stool softener.

Where to Begin Your GLP-1 Journey

Choosing the right provider is arguably as important as choosing the right medication. Look for platforms that offer baseline lab work, regular follow-ups, transparent pricing, and licensed clinicians who specialize in obesity medicine or metabolic health.